iOmx Therapeutics AG has named Apollon Papadimitriou as Chief Executive Officer.
ADVERTISEMENT
After the departure of Peer Schatz, Thierry Bernard is taking over as interim Chief Executive Officer at QIAGEN while the molecular diagnostics company is looking for a permanent head.
John Dombrosky is taking over the helm of the newly founded Oerth Bio, a targeted protein degradation joint venture launched by Bayer and US biotech Arvinas.
It is a brand-new role at Bournemouth-based Life Sciences company Solentim: Mark Stockdale will join the global leader in cell line development instrumentation as as Amalgamator of Business and Biology.
Biom’up SA, specialising in surgical hemostasis, appointed Patrice Ferrand as their new CEO. Ferrand replaces Jan Ohrstrom, who was appointed CEO since May and remains Chairman of the Board.
H.E.L. Group Ltd has a new CEO: The global manufacturer of laboratory tools for process optimisation, safety and scale-up announced the appointment of Louise Madden as Chief Executive Officer.
Edwin Klumper of Lytix Biopharma has stepped down from his role as CEO. The board has decided to promote Head of R&D Øystein Rekdal to the position of CEO.
British cell therapy expert Mogrify Ltd has appointed Jane Osbourn as Chair of the Board. Osbourn will also become a Member of the Scientific Advisory Board and support Mogrifiys executive team in therapeutic programme selection, industrial partner development, mentoring and investor relations.
The Board of Directors of Menarini Group has appointed Mrs. Elcin Barker Ergun as CEO.
PDC*line Pharma, a clinical stage biotech company developing a new class of immunotherapies for cancers announced today that Dr Channa Debruyne joined the company in August as medical director to lead the clinical research team.